Earnings Call
Aug 5, 2026
Q2 FY2026
EPS Estimate
1.87
EPS Actual
2.58
Post-Earnings Close
$99.12
Earnings Reaction
-5.1%
CVS Health delivered a materially stronger-than-expected second quarter, with adjusted EPS of $2.58 against a consensus estimate of $1.86, a beat of roughly 39%, and revenue of approximately $106 billion, comfortably ahead of the $100 billion estimate. The breadth of the outperformance is notable: all three operating segments grew both revenue and adjusted operating income year-over-year, a milestone that reflects the cumulative payoff of multi-year restructuring efforts rather than any single one-time item. Management responded by raising full-year 2026 adjusted EPS guidance by $0.60 to a range of $7.90, $8.10 and lifting the cash flow from operations outlook by $2 billion to at least $11.5 billion.
Report generated on Aug 6, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full CVS analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.